Name (Synonyms) | Correlation | |
---|---|---|
drug360 | Biosensors Wiki | 1.00 |
drug1163 | Ibrutinib Wiki | 0.71 |
drug332 | Best Practice Wiki | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
D000741 | Anemia, Aplastic NIH | 1.00 |
D010265 | Paraproteinemias NIH | 1.00 |
D008218 | Lymphocytosis NIH | 1.00 |
D009190 | Myelodysplastic Syndromes NIH | 0.58 |
D009369 | Neoplasms, NIH | 0.22 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100827 | Lymphocytosis HPO | 1.00 |
HP:0012133 | Erythroid hypoplasia HPO | 1.00 |
HP:0002863 | Myelodysplasia HPO | 0.58 |
HP:0002664 | Neoplasm HPO | 0.22 |
There is one clinical trial.
This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help improve COVID-19 symptoms by lessening the inflammatory response in the lungs, while preserving overall immune function. This may reduce the need to be on a ventilator to help with breathing.
Description: Associations between baseline characteristics and the primary endpoint will be evaluated with logistic regression, adjusting for arm. These analyses will be largely descriptive, as a result of a limited sample size.
Measure: Proportion of patients with diminished respiratory failure and death Time: During hospitalization for COVID-19 infection or within 30 days of registrationDescription: Fever-free will be assessed by a temperature of < 100.5 degrees Fahrenheit orally. Will be estimated for each arm using the method of Kaplan-Meier. Medians estimates and/or estimates at specific time points will be provided with 95% confidence intervals.
Measure: Time from study initiation to 48 hours fever-free Time: Up to 14 daysDescription: Will be estimated for each arm using the method of Kaplan-Meier. Medians estimates and/or estimates at specific time points will be provided with 95% confidence intervals.
Measure: Duration of hospitalization Time: Up to 14 daysDescription: Adverse events will be summarized by grade, type, and attribution (regardless of attribution and treatment-related) for each arm.
Measure: Incidence of grade 3 or higher adverse events Time: Up to 12 monthsDescription: The proportion of patients with viral clearance at the time of hospital discharge will be estimated with 95% confidence intervals for each arm.
Measure: At the end of therapy (day 14) Time: Up to 14 daysDescription: Will be estimated for each arm using the method of Kaplan-Meier. Medians estimates and/or estimates at specific time points will be provided with 95% confidence intervals.
Measure: Time to viral clearance Time: Up to 12 monthsDescription: Patients will be followed for up to 12 months or until death or withdrawal of study consent for further follow-up. Following hospitalization, study visits will be telephone or video encounters.
Measure: Survival Time: Up to12 months